Allergy Therapeutics plc

Equities

AGY

GB00B02LCQ05

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 08:53:40 17/07/2024 BST			5-day change	1st Jan Change
5.275 ^GBX	-4.09%		-4.09%	+111.00%

06-27	Allergy Therapeutics plc Appoints David Ball as Non- Executive Director and Chair of the Board's Audit and Risk Committee	CI
06-10	AIM WINNERS & LOSERS: Arecor Therapeutics dives on funding needs	AN

Allergy Therapeutics plc Provides Revenue Guidance for the Six Months Ended 31 December 2022

January 20, 2023 at 07:00 am

Allergy Therapeutics plc provided revenue guidance for the six months ended 31 December 2022. For the period, the company expects revenue to be £39.9 million (2021: £48.7 million) representing a reduction of 18% compared to last year.

Latest news about Allergy Therapeutics plc

Allergy Therapeutics plc Appoints David Ball as Non- Executive Director and Chair of the Board's Audit and Risk Committee	06-27	CI
AIM WINNERS & LOSERS: Arecor Therapeutics dives on funding needs	06-10	AN
Allergy Therapeutics welcomes peanut allergy vaccine trial results	06-10	AN
Abingdon Health buys IVDeology Holdings	05-07	AN
Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL	05-07	CI
Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director	04-03	CI
EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line	03-27	AN
Allergy Therapeutics Gets OK to Draw Down GBP15 Million From Amended Loan Facility	03-27	MT
AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue	03-27	AN
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Reports Fiscal H1 Revenue GBP33.6M	03-27	MT
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Posts Fiscal H1 Loss GBX-0.58	03-27	MT
Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024	03-27	CI
Allergy Therapeutics plc Reports Earnings Results for the Half Year Ended December 31, 2023	03-27	CI
Allergy Therapeutics starts dosing patients in peanut allergy trial	03-12	AN
Allergy Therapeutics Announces Commencement of Subcutaneous Dosing of Peanut Allergic Patients in the Phase I/IIa PROTECT Trial Evaluating its Novel Virus-Like Particle Based Peanut Allergy Vaccine Candidate	03-12	CI
Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors	03-11	CI
Allergy Therapeutics forecasts revenue drop but trials going well	02-14	AN
Alliance Pharma appoints chair; FireAngel sales down	02-05	AN
Scancell's Chief Development Officer to Step Down	02-05	MT
Allergy Therapeutics resumes trading on AIM; annual revenue plunges	01-30	AN
Allergy Therapeutics amends facility, plans warrant issue	12-27	AN
Allergy Therapeutics Agrees Amendment to Loan Facility	12-27	MT
EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens	12-15	AN
Allergy Therapeutics' Allergic Rhinoconjunctivitis Treatment Returns Positive Data in Late-stage Trial	12-13	MT
Allergy Therapeutics shares jump as hails grass allergy jab data	12-13	AN

Chart Allergy Therapeutics plc

Duration

Period

More charts

Company Profile

Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.

Sector

Biotechnology & Medical Research

Calendar

24/09/2024 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ALLERGY THERAPEUTICS PLC	+111.00%	340M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B
ARGENX SE	+24.05%	27.87B
BIONTECH SE	-17.74%	20.95B
GENMAB A/S	-15.22%	16.92B
BEIGENE, LTD.	-15.21%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B

Bio Therapeutic Drugs